Catalent (NYSE:CTLT) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Catalent (NYSE:CTLT) in a report issued on Friday. The brokerage issued a hold rating on the stock.

Other analysts also recently issued research reports about the company. William Blair restated a “market perform” rating on shares of Catalent in a research note on Tuesday, September 3rd. Robert W. Baird reissued a “neutral” rating and issued a $63.50 target price on shares of Catalent in a research note on Tuesday, September 24th. Finally, Baird R W lowered Catalent from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. Eight investment analysts have rated the stock with a hold rating, According to MarketBeat.com, Catalent presently has an average rating of “Hold” and a consensus price target of $63.40.

Catalent Stock Performance

Shares of CTLT stock opened at $63.48 on Friday. The company’s fifty day moving average price is $60.89 and its 200-day moving average price is $59.62. The stock has a market cap of $11.52 billion, a PE ratio of -28.09, a price-to-earnings-growth ratio of 2.70 and a beta of 1.15. The company has a current ratio of 2.51, a quick ratio of 1.96 and a debt-to-equity ratio of 1.38. Catalent has a 12 month low of $41.15 and a 12 month high of $63.50.

Catalent (NYSE:CTLT) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of $0.05 by ($0.18). Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. The business had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.06 billion. During the same period in the previous year, the firm earned ($0.10) EPS. The company’s revenue was up 4.2% on a year-over-year basis. On average, equities analysts expect that Catalent will post 0.78 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Michelle R. Ryan sold 2,800 shares of the business’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $59.70, for a total transaction of $167,160.00. Following the completion of the transaction, the director now directly owns 10,835 shares of the company’s stock, valued at $646,849.50. The trade was a 20.54 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.31% of the company’s stock.

Institutional Investors Weigh In On Catalent

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Brooklyn Investment Group purchased a new position in Catalent in the third quarter worth about $31,000. Sentry Investment Management LLC purchased a new position in shares of Catalent in the third quarter worth approximately $53,000. Longfellow Investment Management Co. LLC boosted its holdings in shares of Catalent by 45.7% in the second quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock worth $55,000 after buying an additional 305 shares during the last quarter. Thurston Springer Miller Herd & Titak Inc. grew its position in Catalent by 57.5% during the third quarter. Thurston Springer Miller Herd & Titak Inc. now owns 1,181 shares of the company’s stock valued at $72,000 after buying an additional 431 shares during the period. Finally, Intact Investment Management Inc. purchased a new stake in Catalent during the third quarter valued at approximately $73,000.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.